Document:

Exhibit
10.1

 

THIRD
AMENDMENT TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT

UC
Control Number 2019-04-0625

 

THIS
THIRD AMENDMENT (the “ Third Amendment”), dated May 9, 2022 (the “ Third Amendment’s Effective Date”),
is made by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (“The Regents”), a California corporation
having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through
the offices of the Technology Development Group of The University of California, Los Angeles located at 10889 Wilshire Blvd, Suite
920, Los Angeles, CA 90095-7191, and BONE BIOLOGICS CORPORATION (“Licensee”), having a principal place
of business at 2 Burlington Woods Drive, Suite 100, Burlington, Massachusetts, 01803 and amends the Amended and Restated Exclusive
License Agreement with Licensee, dated March 21, 2019 and effective as of dated March 15, 2006 with UC Agreement Control Number 2019-04-0625
and the First Amendment dated August 13, 2020 and the Second amendment dated June 30, 2021 with UC Control No. 2019-04-0625B (collectively,
the “License Agreement”) in accordance with the terms and conditions of this Third Amendment.

 

RECITALS

 

WHEREAS,
Licensee desires to extend certain Development Milestone deadlines under the License Agreement and The Regents is willing to agree to
such extensions on the condition that Licensee pays the Diligence Fee as outlined herein below.

 

NOW
THEREFORE, in consideration of the foregoing premises and the mutual promises, covenants, and agreements hereinafter set forth, all
parties to this Third Amendment mutually agree to amend the License Agreement as follows:

 

1.
In consideration for The Regents’ willingness to extend the fifteen (15) Development Milestone deadlines defined by Section 6.3e-6.3s
below, Licensee agrees to pay the Diligence Fee as described herein below. Therefore, in view of the foregoing, the following Diligence
Fee obligation is added to Section 6.3:

 

“In
consideration for The Regents agreeing to extend the fifteen (15) Development Milestones defined by Sections 6.3e-6.3s as effectuated
by the Third Amendment, Licensee shall pay to The Regents a fee (the “Diligence Fee”) of $533,333.33 per Development
Milestone extension for a total of eight million dollars ($8,000,000) in partial consideration of the lost patent lifetime of the Regents’
Patent Rights that such diligence timeline and any extensions thereto caused.

 

In
order to enable Licensee to preserve available capital and resources for the development of Licensed Products, The Regents is willing
to allow Licensee to defer payment of the Diligence Fee until Licensee or any of its Sublicensees sell any product or service in the
Field of Use that:

 

	 	(i)	includes,
    incorporates, or is provided through the use of NELL-1, Pegylated NELL-1, or an isoform, modification, or derivative thereof, and/or
    
	 	 	 
	 	(ii)	as
    of the date of this Third Amendment, is (or if such sale takes place after all of the Regents’ Patent Rights have expired,
    such sold product or service would have been as of the date of this Third Amendment) a Licensed Product or Licensed Method,

 

(the
date of such sale referred to as the “Triggering Sale Date” and such potential product or service referred to as a
“Qualifying Product or Service”) in accordance with the payment schedule below. Notwithstanding any statement in,
or provision of, this Agreement, Licensee’s obligation to pay the Diligence Fee will survive termination or expiration of this
Agreement and Licensee is prohibited from assigning, selling, or otherwise transferring any of its assets related to any Qualifying Product
or Service unless Licensee’s foregoing Diligence Fee obligation is assigned, sold, or transferred along with such assets, or unless
Licensee pays The Regents the Diligence Fee within ten (10) days of such assignment, sale or other transfer of such rights to any Qualifying
Product or Service.

 

	 	●	Due
    upon cumulative Net Sales equaling $50,000,000 following the Triggering Sale Date - $2,000,000;
	 	●	Due
    upon cumulative Net Sales equaling $100,000,000 following the Triggering Sale Date - $2,000,000; and
	 	●	Due
    upon cumulative Net Sales equaling $200,000,000 following the Triggering Sale Date - $4,000,000.”

 

    	1

     

    

 

	2.	Delete
    Sections 6.3e – 6.3r of the License Agreement in their entirety and replace them with the following:
	 	 	 
	 	6.3e
    	Initiate
    a Phase I/II Pilot Study with respect to a Licensed Product or Licensed Method within the earlier of (i) six (6) months after pilot
    clinical cGMP production, and (ii) December 31st, 2024;
	 	 	 
	 	6.3f	Until
    the date Licensee or a Sublicensee (or an entity acting on behalf of either of the foregoing) completes a Phase III Pivotal Study
    with respect to a Licensed Product or Licensed Method, Licensee or a Sublicensee must spend at least one million dollars ($1,000,000)
    per calendar year on pre-clinical or clinical development of a Licensed Product or Licensed Method. For the avoidance of doubt, such
    amounts shall include solely out-of-pocket costs incurred by Licensee or its Affiliates or Sublicensees in connection with pre-clinical
    or clinical development activities with respect to Licensed Products or Licensed Methods – Licensee and its Sublicensees may
    not allocate or attribute to such total spend any internal costs and overhead, any amounts paid to The Regents under this Agreement
    (such as, for example, for patent cost reimbursement) or incurred in negotiating this Agreement, or any amounts spent in relation
    to the Development Milestones defined by Section 6.3j-s below or any other product or service. Licensee must provide with its semi-annual
    progress reports sufficient documentation substantiating to The Regents’ satisfaction that Licensee and its Sublicensees has
    spent such amount during each applicable year.
	 	 	 
	 	6.3g	Submit
    a PMA application (or foreign equivalent) with respect to a Licensed Product or Licensed Method within twelve (12) months after completing
    a Phase III Pivotal Study with respect to a Licensed Product or Licensed Method;
	 	 	 
	 	6.3h	Achieve
    FDA (or foreign equivalent) or PMA approval (market approval) (or foreign equivalent) for a Licensed Product or Licensed Method within
    twelve (12) months after achieving the Development Milestone defined by Section 6.3g; and
	 	 	 
	 	6.3i	Achieve
    a First Commercial Sale of a Licensed Product or Licensed Method within six (6) months after achieving the Development Milestone
    defined by Section 6.3h.
	 	 	 
	With
    respect to a pegylated Licensed Product covered by the Newly Added Patent Rights:
	 
	 	6.3j	Complete
    a pre-clinical rhNELL-1 chemically modified vs. drug delivery & route and frequency of administration within the earlier of (i)
    six (6) months after Phase I/II Pilot Study is completely enrolled, or (ii) December 31st, 2026;
	 	 	 
	 	6.3k	Enter
    into a contract with contract manufacturing organization (CMO) and complete an animal pilot study to determine what clinical indication
    Licensee intends to pursue no later than twelve (12) months after achieving the Development Milestone defined by Section 6.3j;
	 	 	 
	 	6.3l	Submit
    a pre-IND package to the FDA with respect to a Licensed Product that contains chemistry, manufacturing, and controls (CMC), preclinical
    work, and a clinical development plan no later than six (6) months after achieving the Development Milestone defined by Section 6.3k;
	 	 	 
	 	6.3m	Initiate
    a pivotal animal study in sheep or non-human primates no later than 6 months after achieving the Development Milestone defined by
    Section 6.3l;
	 	 	 
	 	6.3n	File
    an IND with the FDA no later than twenty-four (24) months after achieving the Development Milestone defined by Section 6.3m;
	 	 	 
	 	6.3o	Dose
    a first patient in a Phase I/IIa Clinical Trial no later than twelve (12) months after achieving the Development Milestone defined
    by Section 6.3n;
	 	 	 
	 	6.3p	Dose
    a first patient in a Phase IIb Clinical Trial no later than twelve (12) months after achieving the Development Milestone defined
    by Section 6.3o;
	 	 	 
	 	6.3q	Dose
    a first patient in a Phase III Clinical Trial no later than twenty-four (24) months after achieving the Development Milestone defined
    by Section 6.3p;
	 	 	 
	 	6.3r	Obtain
    FDA approval no later than thirty-six (36) months after achieving the Development Milestone defined by Section 6.3q;
	 	 	 
	 	6.3s	Achieve
    a First Commercial Sale of a Licensed Product or Licensed Method no later than six (6) months after achieving the Development Milestone
    defined by Section 6.3r.

 

All
other terms and conditions of the License Agreement remain the same. This Third Amendment may be executed in two or more counterparts,
each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Electronic, facsimile,
Portable Document Format (PDF) or photocopied signatures of the Parties will have the same legal validity as original signatures.

 

    	2

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Third Amendment by their duly authorized representatives for good and valuable consideration.

 

	BONE
    BIOLOGICS CORPORATION	 	THE
    REGENTS OF THE UNIVERSITY OF CALIFORNIA
	 	 	 
	By	 	 	By	 
	Signature	 	Signature
	Name:	Jeffrey
    Frelick	 	Name: 	Mark
    Wisniewski
	Title:	President
    and CEO	 	Title:	Sr.
    Director Biopharmaceuticals
	 	 	 	 	 
	Date:	 	 	Date	 

 

	 	THE
    REGENTS OF THE UNIVERSITY OF CALIFORNIA
	 	 	 
	 	By	 
	 	Signature
    
	 	Name: 	Amir
    Naiberg
	 	Title:	Assoc.
Vice Chancellor and President & CEO

	 	 	 
	 	Date:	 

 

    	3EdgarFiling

Exhibit 10.1

 

COOPERATION AGREEMENT

 

This Cooperation Agreement
(this “Agreement”) is made and entered into as of June 9, 2022 by and among Psychemedics Corporation (the “Company”)
and the entities and natural persons set forth in the signature pages hereto (collectively, “Kamin”) (each of the Company
and Kamin, a “Party” to this Agreement, and collectively, the “Parties”).

 

RECITALS

 

WHEREAS, the Company and Kamin
have engaged in various discussions and communications concerning the Company’s business, financial performance and strategic plans;

 

WHEREAS, as of the date hereof,
Kamin has a beneficial ownership (as determined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended, or
the rules or regulations promulgated thereunder (the “Exchange Act”)) interest in the Common Stock,  par value
$0.005 per share, of the Company (the Common Stock”) totaling, in the aggregate, 627,737 shares, or approximately 11.1% of
the Common Stock issued and outstanding on the date hereof;

 

WHEREAS, Kamin submitted a
letter to the Company on May 6, 2022 (the “Nomination Notice”) nominating three director candidates to be elected to
the Board of Directors of the Company (the “Board”) at the Company’s 2022 Annual Meeting of Stockholders (the
“2022 Annual Meeting”); and

 

WHEREAS, as of the date hereof,
the Company and Kamin have determined to come to an agreement with respect to the composition of the Board and certain other matters,
as provided in this Agreement.

 

NOW, THEREFORE, in consideration
of the foregoing premises and the mutual covenants and agreements contained herein, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound hereby, agree as follows:

 

		1.	Board Appointments and Related Agreements.

 

(a)            Board
Appointments

 

(i)             
In connection with the Company’s 2022 Annual Meeting, the Company agrees that the Board and all applicable committees of
the Board shall promptly take all necessary actions to (A) increase the size of the Board from five (5) to six (6) directors, (B) nominate
Peter H. Kamin (“PH Kamin”) and Darius G. Nevin (“Nevin”) (each a “New Appointee”
and collectively, the “New Appointees”) for election to the Board at the 2022 Annual Meeting as directors of the Company
for terms expiring at the Company’s 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”). The Company
acknowledges that Walter S. Tomenson, Jr. will retire as a director of the Company upon the conclusion of the 2022 Annual Meeting when
his current term of service expires. The Company shall use its reasonable best efforts to hold the 2022 Annual Meeting no later than August
31, 2022.

 

     

     

    

(ii)          The
Company agrees that (A) the Board shall nominate the New Appointees for election to the Board at the 2022 Annual Meeting, subject to
their consent to serve, for terms expiring at the Company’s 2023 Annual Meeting; and (B) the Company shall recommend, support and
solicit proxies for the New Appointees at the 2022 Annual Meeting in the same manner as it recommends, supports, and solicits proxies
for the election of the Company’s other director nominee.

 

(iii)        
In advance of the 2022 Annual Meeting, the Company agrees to provide, in its reasonable discretion, onboarding materials to each
New Appointee to facilitate their readiness to join the Board upon election at the 2022 Annual Meeting, including without limitation prior
board meeting materials and minutes, strategic plans, operating budgets, organizational charts, and any relevant compensation plans or
arrangements, as reasonably requested by the New Appointees (collectively, the “Onboarding Information”); provided
that the Company shall not be required to provide any Onboarding Information that would be reasonably be expected to compromise attorney-client
privilege. The New Appointees’ receipt of the Onboarding Information shall be subject to a non-disclosure agreement with the Company
to be agreed between the Parties.

 

(iv)         
If at any time prior to the expiration of the Standstill Period (as defined below), (x) Nevin (or any Replacement Director) is
unable or unwilling to serve as a director and ceases to be a director, resigns as a director, is removed as a director, or for any other
reason fails to serve or is not serving as a director or (y) PH Kamin is physically unable to serve as a director due to injury or disability,
and at such time (A) Kamin beneficially owns (as determined under Rule 13d-3 promulgated under the Exchange Act) in the aggregate at least
the lesser of 10% of the Company’s then-outstanding Common Stock and 562,620 shares of Common Stock (subject to adjustment for stock
splits, reclassifications, combinations and similar adjustments) (the “Minimum Ownership Threshold”) and (B) Kamin
has not committed a material breach of this Agreement (except to the extent where such breach is capable of being cured, Kamin has cured
such breach within 10 days’ of receipt of written notice of such breach from the Company), Kamin shall have the ability to recommend
a person to be a replacement director in accordance with this Section 1(a)(iv) (any such replacement nominee, when appointed to
the Board, shall be referred to as a “Replacement Director”). Any Replacement Director must (A) be reasonably acceptable
to the Board (such acceptance not to be unreasonably withheld), (B) qualify as “independent” pursuant to Nasdaq listing standards
and (C) have the relevant financial and business experience to be a director of the Company. The Nominating Committee shall make its determination
and recommendation regarding whether such proposed Replacement Director meets the foregoing criteria within five (5) business days after
(1) such nominee has submitted to the Company the documentation required by Section 1(c)(iv) and (2) representatives of the Board
have conducted customary interview(s) of such nominee, if such interviews are requested by the Board or the Nominating Committee. The
Company shall use its reasonable best efforts to conduct any interview(s) contemplated by this Section 1(a)(iv) as promptly as
practicable, but in any case, assuming reasonable availability of the nominee, within ten (10) business days after Kamin’s submission
of such nominee. In the event the Nominating Committee does not accept a person recommended by Kamin as the Replacement Director, Kamin
shall have the right to recommend additional substitute person(s) whose appointment shall be subject to the Nominating Committee recommending
such person in accordance with the procedures described above. Upon the recommendation of a Replacement Director nominee by the Nominating
Committee, the Board shall vote on the appointment of such Replacement Director to the Board no later than five (5) business days after
the Nominating Committee’s recommendation of such Replacement Director; provided, however, that if the Board does
not appoint such Replacement Director to the Board pursuant to this Section 1(a)(iv), the Parties shall continue to follow the
procedures of this Section 1(a)(iv) until a Replacement Director is elected to the Board for the 2022 term. Subject to Nasdaq rules
and applicable law, upon a Replacement Director’s appointment to the Board, the Board and all applicable committees of the Board
shall take all necessary actions to appoint such Replacement Director to any applicable committee of the Board of which the replaced director
was a member immediately prior to such director’s resignation or removal. Subject to Nasdaq rules and applicable law, until such
time as any Replacement Director is appointed to any applicable committee of the Board, the other New Appointee will serve as an interim
member of such applicable committee. Any Replacement Director designated pursuant to this Section 1(a)(iv) replacing a New Appointee prior
to the mailing of the Company’s definitive proxy statement for the 2022 Annual Meeting shall stand for election at the 2022 Annual
Meeting together with the other director nominees. Following the appointment of any Replacement Director to replace a New Appointee in
accordance with this Section 1(a)(iv), all references to such New Appointee herein shall be deemed to include any Replacement Director
(it being understood that this sentence shall apply whether or not references to the New Appointees expressly state that they include
any Replacement Director).

 

    	2

     

    

(v)           
During the Standstill Period (as defined below), the Board and all applicable committees of the Board shall not increase the size
of the Board to more than six (6) directors without the unanimous consent of the Board.

 

(b)            Board
Committees.

 

(i)             
Strategic Alternatives Committee.

 

Immediately following
the election of the New Appointees to the Board at the 2022 Annual Meeting, the Board and all applicable committees of the Board shall
take all necessary actions to appoint the New Appointees to the existing committee of the Board designated to review shareholder enhancement
opportunities (the “Strategic Alternatives Committee”). During the Standstill Period, unless otherwise agreed to by
the Strategic Alternatives Committee, the Strategic Alternatives Committee shall be composed of four (4) directors, including the New
Appointees (or any Replacement Director, as the case may be).

 

(ii)           
Other Committee Assignments.

 

In addition to appointing the
New Appointees to the Strategic Alternatives Committee, immediately following the election of the New Appointees to the Board at the 2022
Annual Meeting, the Board and all applicable committees of the Board shall take all actions necessary to appoint (i) Mr. Kamin to the
Compensation Committee of the Board and the Nominating Committee of the Board and (ii) Mr. Nevin to the Audit Committee and Compensation
Committee of the Board. If any new committee(s) or subcommittee(s) is established during the Standstill Period, the Board and all applicable
committees of the Board shall take all actions necessary to ensure that at least one (1) New Appointee (or a Replacement Director, if
applicable) is appointed to such new committee or subcommittee, assuming such person satisfies any applicable independence or other criteria
of the Nasdaq rules or SEC regulations.

 

    	3

     

    

(c)            Additional
Agreements.

 

(i)             Kamin,
on behalf of himself and his controlled Affiliates and Associates, hereby irrevocably withdraws his Nomination Notice and any related
materials or notices submitted to the Company in connection therewith. During the Standstill Period, except as otherwise provided herein,
Kamin shall not, and shall cause each of its controlled Affiliates and Associates not to, directly or indirectly, (A) nominate or recommend
for nomination any person for election at any annual or special meeting of the Company’s stockholders, (B) submit any proposal
for consideration at, or bring any other business before, any annual or special meeting of the Company’s stockholders, or (C) initiate,
encourage or participate in any “vote no,” “withhold” or similar campaign with respect to any annual
or special meeting of the Company’s stockholders. Kamin shall not publicly or privately encourage or support any other stockholder,
person or entity to take any of the actions described in this Section 1(c)(i).

 

(ii)          
Kamin shall appear in person or by proxy at the 2022 Annual Meeting and vote all shares of Common Stock beneficially owned by Kamin
at the 2022 Annual Meeting (A) in favor of all directors nominated by the Board for election, (B) in favor of the ratification of the
appointment of BDO USA, LLP as the Company’s registered public accounting firm for the fiscal year ended December 31, 2022, (C)
in accordance with the Board’s recommendation with respect to the Company’s “say-on-pay” proposal and (D) in accordance
with the Board’s recommendation with respect to any other Company proposal or stockholder proposal or nomination presented at the
2022 Annual Meeting; provided, however, that in the event Institutional Shareholder Services Inc. (“ISS”)
and Glass Lewis & Co., LLC (“Glass Lewis”) recommends otherwise with respect to the Company’s “say-on-pay”
proposal or any other Company proposal or stockholder proposal presented at the 2022 Annual Meeting (other than proposals relating to
the election of directors), Kamin shall be permitted to vote in accordance with the ISS and Glass Lewis recommendation. Kamin further
agrees that he will appear in person or by proxy at any special meeting of the Company’s shareholders held during the Standstill
Period and, to the extent any such special meeting includes the election of directors, vote all shares of Common Stock beneficially owned
by Kamin at such special meeting in accordance with the Board’s recommendation(s) on any proposal relating to the appointment, election
or removal of directors.

 

(iii)        
Kamin acknowledges that each New Appointee is required to submit to the Company a fully completed copy of the Company’s standard
director & officer questionnaire and other reasonable and customary director onboarding documentation applicable to directors of the
Company.

 

(iv)         
 The Company agrees that the Board and all applicable committees of the Board shall, to the extent that the Board and such committees
have such authority and are entitled to so determine, take all necessary actions to determine, in connection with the Company’s
nomination of the New Appointees to the Board at the 2022 Annual Meeting and any subsequent appointment of the New Appointees as directors,
that each of the New Appointees will be deemed to be “Indemnitee(s)” under the Company’s Indemnification Agreements.

 

    	4

     

    

		2.	Standstill Provisions.

 

(a)              Kamin
agrees that, from the date of this Agreement until the earlier of (x) the date that is twenty (20) business days prior to the deadline
for the submission of stockholder nominations for the 2023 Annual Meeting pursuant to the Company’s Amended and Restated Bylaws
or (y) the date that is one hundred (100) days prior to the first anniversary of the 2022 Annual Meeting (the “Standstill Period”),
Kamin shall not, and shall cause each of its controlled Affiliates and Associates not to, in each case directly or indirectly, in any
manner:

 

(i)           acquire,
or offer, seek or agree to acquire, by purchase or otherwise, or direct any third party in the acquisition of, any Common Stock or any
securities convertible or exchangeable into or exercisable for Common Stock (collectively, “Company Securities”) or
assets of the Company, or rights or options to acquire any Company Securities, or engage in any swap instrument or derivative hedging
transactions or other derivative agreements of any nature with respect to Company Securities that would result in Kamin having beneficial
ownership (as determined under Rule 13d-3 promulgated under the Exchange Act) of more than 14.99% of the Common Stock outstanding at
such time;

 

(ii)          engage
in any solicitation of proxies or become a “participant” in a “solicitation” (as such terms are
defined in Regulation 14A under the Exchange Act) of proxies (including, without limitation, any solicitation of consents that seeks
to call a special meeting of stockholders), in each case, with respect to securities of the Company;

 

(iii)        
make any request for a stockholder list of materials or any other books and records of the Company under Section 220 of the Delaware
General Corporation Law or otherwise;

 

(iv)         form,
join, or in any way knowingly participate in any “group” (within the meaning of Section 13(d)(3) of the Exchange Act)
with respect to the shares of the Common Stock (other than a “group” that includes all or some of the members of Kamin,
but does not include any other entities or persons that are not members of Kamin as of the date hereof); provided, however,
that nothing herein shall limit the ability of an Affiliate of Kamin to join the “group” following the execution of
this Agreement, so long as any such Affiliate agrees to be bound by the terms and conditions of this Agreement;

 

(v)          deposit
any shares of Common Stock in any voting trust or subject any shares of Common Stock to any arrangement or agreement with respect to
the voting of any shares of Common Stock, other than any such voting trust, arrangement or agreement solely among the members of Kamin
and otherwise in accordance with this Agreement;

 

(vi)           seek
or submit, or knowingly encourage any person or entity to seek or submit, nomination(s) in furtherance of a “contested solicitation”
for the appointment, election or removal of directors with respect to the Company or seek, or knowingly encourage or take any other action
with respect to the appointment, election or removal of any directors, in each case in opposition to the recommendation of the Board;

 

(vii)      
(A) make any proposal for consideration by stockholders at any annual or special meeting of stockholders of the Company, (B) make
any offer or proposal (with or without conditions) with respect to any merger, tender (or exchange) offer, consolidation, acquisition,
recapitalization, restructuring, liquidation, dissolution, disposition or other business combination involving the Company, (C) affirmatively
solicit a third party to make an offer or proposal (with or without conditions) with respect to any merger, tender (or exchange) offer,
consolidation, acquisition, recapitalization, restructuring, liquidation, dissolution, disposition or other business combination involving
the Company, or publicly encourage, initiate or support any third party in making such an offer or proposal, (D) publicly comment on any
third party proposal regarding any merger, tender (or exchange) offer, consolidation, acquisition, recapitalization, restructuring, liquidation,
dissolution, disposition, or other business combination with respect to the Company by such third party prior to such proposal becoming
public or (E) call or seek to call a special meeting of stockholders;

 

    	5

     

    

(viii)       seek,
alone or in concert with others, representation on the Board, except as specifically permitted in Section 1;

 

(ix)         
advise, knowingly encourage, knowingly support or knowingly influence any person or entity with respect to the voting or disposition
of any securities of the Company at any annual or special meeting of stockholders with respect to the appointment, election or removal
of director(s), except in accordance with Section 1; or

 

(x)           make
any request or submit any proposal, alone or in concert with others, that would reasonably be expected to require the Company or Kamin
to make public disclosure of any kind, other than through non-public communications with the Company or the Board that would not be reasonably
determined to trigger public disclosure obligations for any Party.

 

(b)            Except as expressly provided in Section 1, Section 2(a) or Section 12, Kamin shall be entitled to (i) vote
any shares of Common Stock that it beneficially owns as Kamin determines in its sole discretion and (ii) disclose, publicly or otherwise,
how it intends to vote or act with respect to any securities of the Company, any stockholder proposal or other matter to be voted on by
the stockholders of the Company and the reasons therefor.

 

(c)            Nothing in Section 2(a) shall be deemed to limit the exercise in good faith by any New Appointee (or a Replacement Director)
of such person’s fiduciary duties solely in such person’s capacity as a director of the Company.

 

		3.	Representations and Warranties of the Company.

 

The Company represents and
warrants to Kamin that (a) the Company has the corporate power and authority to execute this Agreement and to bind it thereto, (b) this
Agreement has been duly and validly authorized, executed and delivered by the Company, and assuming due execution by each counterparty
hereto, constitutes a valid and binding obligation and agreement of the Company, and is enforceable against the Company in accordance
with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent
conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles, and (c) the execution,
delivery and performance of this Agreement by the Company does not and will not (i) violate or conflict with any law, rule, regulation,
order, judgment or decree applicable to the Company, or (ii) result in any breach or violation of or constitute a default (or an event
which with notice or lapse of time or both would constitute such a breach, violation or default) under or pursuant to, or result in the
loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document
or material agreement to which the Company is a party or by which it is bound.

 

    	6

     

    

		4.	Representations and Warranties of Kamin.

 

Kamin represents and warrants
to the Company that (a) the authorized signatory of Kamin set forth on the signature page hereto has the power and authority to execute
this Agreement and any other documents or agreements to be entered into in connection with this Agreement and to bind Kamin thereto, (b)
this Agreement has been duly authorized, executed and delivered by Kamin, and assuming due execution by each counterparty hereto, is a
valid and binding obligation of Kamin, enforceable against Kamin in accordance with its terms except as enforcement thereof may be limited
by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights
of creditors and subject to general equity principles, (c) the execution of this Agreement, the consummation of any of the transactions
contemplated hereby, and the fulfillment of the terms hereof, in each case in accordance with the terms hereof, will not conflict with,
or result in a breach or violation of the organizational documents of Kamin as currently in effect, (d) the execution, delivery and performance
of this Agreement by Kamin does not and will not (i) violate or conflict with any law, rule, regulation, order, judgment or decree applicable
to Kamin, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both
would constitute such a breach, violation or default) under or pursuant to, or result in the loss of a material benefit under, or give
any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding
or arrangement to which such member is a party or by which it is bound, (e) as of the date of this Agreement, Kamin is deemed to beneficially
own 627,737 shares of Common Stock, (f) as of the date hereof, and except as set forth in clause (e) above, Kamin does not currently have,
and does not currently have any right to acquire, any interest in any securities or assets of the Company or its Affiliates (or any rights,
options or other securities convertible into or exercisable or exchangeable (whether or not convertible, exercisable or exchangeable immediately
or only after the passage of time or the occurrence of a specified event) for such securities or assets or any obligations measured by
the price or value of any securities of the Company or any of its controlled Affiliates, including any swaps or other derivative arrangements
designed to produce economic benefits and risks that correspond to the ownership of shares of Common Stock or any other securities of
the Company, whether or not any of the foregoing would give rise to beneficial ownership (as determined under Rule 13d-3 promulgated under
the Exchange Act), and whether or not to be settled by delivery of shares of Common Stock or any other class or series of the Company’s
stock, payment of cash or by other consideration, and without regard to any short position under any such contract or arrangement) and
(g) Kamin has not (except as disclosed in the Nomination Notice), directly or indirectly, compensated or agreed to compensate, and will
not, directly or indirectly, compensate or agree to compensate, Mr. Nevin for serving as a nominee or director of the Company with any
cash, securities (including any rights or options convertible into or exercisable for or exchangeable into securities or any profit sharing
agreement or arrangement), or other form of compensation, directly or indirectly, related to the Company or its securities. For the avoidance
of doubt, nothing herein shall prohibit Kamin for compensating or agreeing to compensate any person for his or her respective service
as a nominee or director of any other company.

 

    	7

     

    

		5.	Press Release.

 

Promptly following the execution
of this Agreement, the Company and Kamin shall jointly issue a mutually agreeable press release (the “Press Release”)
announcing certain terms of this Agreement in the form attached hereto as Exhibit A. Prior to the issuance of the Press Release
and subject to the terms of this Agreement, neither the Company (including the Board and any committee thereof) nor Kamin shall issue
any press release or make public announcement regarding this Agreement or the matters contemplated hereby without the prior written consent
of the other Party. During the Standstill Period, neither the Company nor Kamin shall make any public announcement or statement that is
inconsistent with or contrary to the terms of this Agreement, except as required by law or the rules of any stock exchange.

 

		6.	Specific Performance.

 

Each of Kamin, on the one
hand, and the Company, on the other hand, acknowledges and agrees that irreparable injury to the other Party hereto would occur in the
event any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached and
that such injury would not be adequately compensable by the remedies available at law (including the payment of money damages). It is
accordingly agreed that Kamin, on the one hand, and the Company, on the other hand (the “Moving Party”), shall each
be entitled to seek specific enforcement of, and injunctive relief to prevent any violation of, the terms hereof, and the other Party
hereto will not take action, directly or indirectly, in opposition to the Moving Party seeking such relief on the grounds that any other
remedy or relief is available at law or in equity. This Section 6 is not the exclusive remedy for any violation of this Agreement.

 

		7.	Expenses.

 

The Company shall reimburse
Kamin for its reasonable, documented out-of-pocket fees and expenses (including legal expenses) incurred in connection with Kamin’s
involvement at the Company through the date of this Agreement promptly upon the conclusion of the 2022 Annual Meeting, including, provided
that such reimbursement shall not exceed $50,000 in the aggregate.

 

		8.	Severability.

 

If any term, provision, covenant
or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, the remainder of the
terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected,
impaired or invalidated. It is hereby stipulated and declared to be the intention of the Parties that the Parties would have executed
the remaining terms, provisions, covenants and restrictions without including any of such which may be hereafter declared invalid, void
or unenforceable. In addition, the Parties agree to use their commercially reasonable best efforts to agree upon and substitute a valid
and enforceable term, provision, covenant or restriction for any of such that is held invalid, void or enforceable by a court of competent
jurisdiction.

 

    	8

     

    

		9.	Notices.

 

Any notices, consents, determinations,
waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed
to have been delivered: (a) upon receipt, when delivered personally; (b) upon confirmation of receipt, when sent by email (provided
such confirmation is not automatically generated); or (c) two (2) business days after deposit with a nationally recognized overnight delivery
service, in each case properly addressed to the Party to receive the same. The addresses and facsimile numbers for such communications
shall be:

 

If to the Company:

 

Psychemedics Corporation

289 Great Road

Acton, Massachusetts 01720

Attention:Ray Kubacki, Chief Executive Officer

E-mail:rayk@psychemedics.com

with a copy (which shall not constitute notice) to:

 

Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C.

One Financial Center

Boston, MA 02111

Attention:Matthew J. Gardella

Telephone:(617) 348-1735

Email:MGardella@mintz.com

 

If to Kamin or any member thereof:

 

3K Limited Partnership

2720 Donald Ross Road, Unit #311

Palm Beach Gardens, Florida 33410

Attention:Peter H. Kamin

Email:pkamin@3klp.com

 

with a copy (which shall not constitute notice) to:

 

Olshan Frome Wolosky LLP

1325 Avenue of the Americas

New York, New York 10019

Attention:Andrew Freedman, Esq.

Facsimile:(212) 451-2222

Email:afreedman@olshanlaw.com

 

    	9

     

    

		10.	Applicable Law.

 

This Agreement shall be governed
by and construed and enforced in accordance with the laws of the State of Delaware without reference to the conflict of laws principles
thereof that would result in the application of the law of another jurisdiction. Each of the Parties hereto irrevocably agrees that any
legal action or proceeding with respect to this Agreement and the rights and obligations arising hereunder, or for recognition and enforcement
of any judgment in respect of this Agreement and the rights and obligations arising hereunder brought by the other Party hereto or its
successors or assigns, shall be brought and determined exclusively in the Delaware Court of Chancery and any state appellate court therefrom
within the State of Delaware (or, if the Delaware Court of Chancery declines to accept jurisdiction over a particular matter, any federal
court within the State of Delaware). Each of the Parties hereto hereby irrevocably submits with regard to any such action or proceeding
for itself and in respect of its property, generally and unconditionally, to the personal jurisdiction of the aforesaid courts and agrees
that it will not bring any action relating to this Agreement in any court other than the aforesaid courts. Each of the Parties hereto
hereby irrevocably waives, and agrees not to assert in any action or proceeding with respect to this Agreement, (a) any claim that it
is not personally subject to the jurisdiction of the above-named courts for any reason, (b) any claim that it or its property is exempt
or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment
prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c) to the fullest extent permitted
by applicable legal requirements, any claim that (i) the suit, action or proceeding in such court is brought in an inconvenient forum,
(ii) the venue of such suit, action or proceeding is improper or (iii) this Agreement, or the subject matter hereof, may not be enforced
in or by such courts.

 

		11.	Counterparts.

 

This Agreement may be executed
in two or more counterparts, each of which shall be considered one and the same agreement and shall become effective when counterparts
have been signed by each of the Parties and delivered to the other Party (including by means of electronic delivery or facsimile). For
the avoidance of doubt, neither Party shall be bound by any contractual obligation to the other Party (including by means of any oral
agreement) until all counterparts to this Agreement have been duly executed by each of the Parties and delivered to the other Party (including
by means of electronic delivery of facsimile).

 

		12.	Mutual Non-Disparagement.

 

Subject to applicable law,
each of the Parties covenants and agrees that, during the Standstill Period, or if earlier, until such time as the other Party or any
of its agents, subsidiaries, affiliates, successors, assigns, officers, key employees or directors shall have breached this Section
12, neither it nor any of its respective agents, subsidiaries, affiliates, successors, assigns, officers, key employees or directors
shall in any way publicly criticize, disparage, call into disrepute or otherwise defame or slander the other Party or such other Party’s
subsidiaries, affiliates, successors, assigns, officers (including any current officer of a Party or a Party’s subsidiaries who
no longer serves in such capacity following the execution of this Agreement), directors (including any current officer or director of
a Party or a Party’s subsidiaries who no longer serves in such capacity in connection with the execution of this Agreement), employees,
stockholders, agents, attorneys or representatives, or any of their businesses, products or services, in any manner that would reasonably
be expected to damage the business or reputation of such other Party, their businesses, products or services or their subsidiaries, affiliates,
successors, assigns, officers (or former officers), directors (or former directors), employees, shareholders, agents, attorneys or representatives.

 

    	10

     

    

		13.	No Litigation.

 

Each Party agrees that, during
the Standstill Period, it shall not institute, solicit, join or assist in any lawsuit, claim or proceeding before any court or government
agency (each, a “Legal Proceeding”) against the other Party, any Affiliate of the other Party or any of their respective
current or former directors or officers, except for (a) any Legal Proceeding initiated primarily to remedy a breach of or to enforce this
Agreement and (b) counterclaims with respect to any proceeding initiated by, or on behalf of one Party or its Affiliates against the other
Party or its Affiliates; provided, however, that the foregoing shall not prevent any Party or any of its Representatives (as hereinafter
defined) from responding to oral questions, interrogatories, requests for information or documents, subpoenas, civil investigative demands
or similar processes (each, a “Legal Requirement”) as required by law in connection with any Legal Proceeding if such
Legal Proceeding has not been initiated by, on behalf of or at the suggestion of such Party; provided, further, that in the event any
Party or any of its Representatives receives such Legal Requirement, such Party shall give prompt written notice of such Legal Requirement
to the other Party (except where such notice would be legally prohibited or not practicable). Each Party represents and warrants that
neither it nor any assignee has filed any lawsuit against the other Party.

 

		14.	Company Policies.

 

The Parties acknowledge that,
except as otherwise provided herein, at all times while serving as a director, the New Appointees shall comply with all company policies,
including but not limited to, codes and guidelines applicable to Company directors, including the Company’s code of ethics and conduct,
corporate governance guidelines, anti-bribery policy, and information security policy.

 

		15.	Securities Laws.

 

Kamin acknowledges that it
is aware, and will advise each of its representatives who are informed as to the matters that are the subject of this Agreement, of the
following: (i) the United States securities laws prohibit any person who directly or indirectly has received from an issuer material,
non-public information from purchasing or selling securities of such issuer or from communicating such information to any other person
under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities, (ii) the anti-insider
trading policy set forth in Section 2.6 of the Company’s Code of Ethics and Conduct and (iii) the provisions of U.S. Securities
and Exchange Commission Regulation Fair Disclosure (“Regulation FD”) requiring the public announcement of previously
non-public material information if that information is disclosed to anyone who has not agreed to maintain the confidentiality of that
information, and each such person agrees to take no action that would require the Company to make a public announcement pursuant to the
requirements of Regulation FD.

 

    	11

     

    

		16.	Entire Agreement; Amendment and Waiver; Successors and Assigns; Third Party Beneficiaries; Term.

 

This Agreement contains the
entire understanding of the Parties with respect to its subject matter. There are no restrictions, agreements, promises, representations,
warranties, covenants or undertakings between the Parties other than those expressly set forth herein. No modifications of this Agreement
can be made except in writing signed by an authorized representative of each the Company and Kamin. No failure on the part of any Party
to exercise, and no delay in exercising, any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single
or partial exercise of such right, power or remedy by such Party preclude any other or further exercise thereof or the exercise of any
other right, power or remedy. All remedies hereunder are cumulative and are not exclusive of any other remedies provided by law. The terms
and conditions of this Agreement shall be binding upon, inure to the benefit of, and be enforceable by the Parties hereto and their respective
successors, heirs, executors, legal representatives, and permitted assigns. No Party shall assign this Agreement or any rights or obligations
hereunder without, with respect to Kamin, the prior written consent of the Company, and with respect to the Company, the prior written
consent of Kamin. This Agreement is solely for the benefit of the Parties and is not enforceable by any other persons or entities. This
Agreement shall terminate at the end of the Standstill Period, except provisions of Section 14, Section 15, and Section
16, which shall survive such termination.

 

[The remainder of this page intentionally left
blank]

 

 

 

 

 

 

 

    	12

     

    

 

IN WITNESS WHEREOF, this Agreement has been duly
executed and delivered by the duly authorized signatories of the Parties as of the date hereof.

 

	 	psychemedics corporation
	 	 
	 	By:	
    /s/ Raymond C. Kubacki

	 	 	Name:	Raymond C. Kubacki
	 	 	Title:	President and Chief Executive Officer

 

 

 

 

 

 

 

 

 

[Signature Page to Agreement]

     

     

    

 

 

	
    3K Limited Partnership

    By: Peter H. Kamin,

    its general partner

     

    Peter H. Kamin Revocable
    Trust dated February 2003

    By: Peter H. Kamin,

    its sole trustee

     

    Peter H. Kamin Childrens
    Trust dated March 1997

    By: Peter H. Kamin,

    its sole trustee  

	 

 

	By:	
    /s/ Peter H. Kamin
	 
	 	Name:	Peter H. Kamin	 
	 	Title:	Authorized Signatory	 

 

 

 

 

 

 

 

 

 

 

[Signature Page to Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]